ArticleJournal of inflammation (London, England)2025
Study of the mechanism of methyltransferase 3 regulation of ferroptosis in allergic rhinitis and promotion of allergic rhinitis in an m6A-dependent mechanism.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to investigate the regulation of allergic rhinitis (AR) by methyltransferase 3 through an m6A-dependent mechanism, providing a theoretical foundation for its treatment.
methodsAn in vitro experiment was conducted in which HNEpC cells were stimulated with IL-13 (50 ng/mL) to create an AR cell model. After establishing the AR cell model, the cells were treated with DAA (m6A inhibitor) and separated into three groups: Control group, shNC group and shMETTL3 group.m6A-RIP assessed the m6A modification level of PTBP1 mRNA, while RIP was used to analyze the interaction between METTL3 and PTBP1 mRNA. On the shMETTL3 background, PTBP1 or TXNIP was re-expressed with or without the ferroptosis inhibitor ferrostatin-1 (Fer-1). Endpoints included serum cytokines/immunoglobulins (IFN-γ, IL-1β, IL-18, TGF-β, IL-4, IL-10, IgE, IgG2a, IgG1) and oxidative-stress indices (GSH, SOD, MDA) by ELISA, alongside nasal-mucosa western blots for GPX4, Nrf2, MnSOD, ACSL4, METTL3, PTBP1, and TXNIP.
resultsIn vitro, shMETTL3 reduced m6A on PTBP1 mRNA and lowered PTBP1 expression. In vivo, the AR condition was associated with higher circulating IFN-γ, IL-1β, IL-18, IL-4, IL-10, IgE, IgG1, and IgG2a, together with lower TGF-β, GSH, and SOD, and a ferroptosis-prone protein profile characterized by reduced GPX4, Nrf2, and MnSOD and increased ACSL4, PTBP1, and TXNIP in nasal mucosa. Silencing METTL3 shifted these readouts toward an anti-oxidant, anti-ferroptotic state, normalizing cytokines/immunoglobulins, raising GSH and SOD while lowering MDA, and restoring a protein pattern with higher GPX4, Nrf2, and MnSOD and lower ACSL4, PTBP1, and TXNIP. Re-expression of PTBP1 or TXNIP on the shMETTL3 background attenuated these improvements and reinstated AR-like oxidative and ferroptotic features. Notably, co-administration of ferrostatin-1 with either overexpression condition re-established antioxidant capacity (higher GSH and SOD with lower MDA) and returned the Western-blot profile toward protection, consistent with a METTL3/PTBP1/TXNIP pathway that promotes ferroptotic and oxidative injury and with the capacity of pharmacologic ferroptosis blockade to counteract it.
conclusionMethyltransferase 3 potentially modulates ferroptosis and oxidative stress linked to AR through an m6A-dependent mechanism, thereby alleviating symptoms in AR mice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.